Page 103 - 南京医科大学自然科学版第1期
P. 103
第41卷第1期 杨颖倩,周德兰,韩男男,等. ⅠB~ⅡA1期宫颈癌术后合并中危因素患者化疗或放疗疗效及
2021年1月 生活质量分析[J]. 南京医科大学学报(自然科学版),2021,41(01):092-097 · 97 ·
[参考文献] carcinoma with risk factors[J]. Jpn J Clin Oncol,2017,47
(1):32-38
[1] SEDLIS A,BUNDY B N,ROTMAN M Z,et al. A random⁃
[9] SHIMADA M,NISHIMURA R,HATAE M,et al,Compar⁃
ized trial of pelvic radiation therapy versus no further ther⁃
ison of adjuvant chemotherapy and radiotherapy in pa⁃
apy in selected patients with stage ⅠB carcinoma of the
tients with cervical adenocarcinoma of the uterus after
cervix after radical hysterectomy and pelvic lymphadenec⁃
radical hysterectomy:SGSG/TGCU intergroup surveil⁃
tomy:a Gynecologic Oncology Group Study[J]. Gynecol
lance[J]. Eur J Gynaecol Oncol,2013,34(5):425-428
Oncol,1999,73(2):177-183
[10] LI L,SONG X,LIU R,et al. Chemotherapy versus radio⁃
[2] RYU S Y,KIM M H,NAM B H,et al. Intermediate⁃risk
therapy for FIGO stages ⅠB1 and ⅡA1 cervical carcino⁃
grouping of cervical cancer patients treated with radical
ma patients with postoperative isolated deep stromal inva⁃
hysterectomy:a Korean Gynecologic Oncology Group
sion:a retrospective study[J]. BMC Cancer,2016,16:
study[J]. Br J Cancer,2014,110(2):278-285
403
[3] LEE K B,KIM Y S,LEE J M. Oncologic outcomes of adju⁃
[11] NAKAMURA K,KITAHARA Y,SATOH T,et al. Analy⁃
vant chemotherapy alone after radical surgery for stage Ⅰ
sis of the effect of adjuvant radiotherapy on outcomes and
B⁃ⅡA cervical cancer patients[J]. Gynecol Oncol,2018,
complications after radical hysterectomy in FIGO stage Ⅰ
29(1):e5
B1 cervical cancer patients with intermediate risk factors
[4] LEE K B,LEE J M,KI K D,et al. Comparison of adjuvant
(GOTIC Study)[J]. World J Surg Oncol,2016,14(1):
chemotherapy and radiation inpatients with intermediate
173
risk factors after radical surgery in FIGO stage ⅠB⁃ⅡA
[12] YU H,ZHANG L,DU X,et al. Postoperative adjuvant che⁃
cervical cancer[J]. Int J Gynecol Cancer,2008,18(5):
motherapy combined with intracavitary brachytherapy in
1027-1031
early⁃stage cervical cancer patients with intermediate risk
[5] JUNG P S,KIM D Y,LEE S W,et al. Clinical role of ad⁃
factors[J]. Onco Targets Ther,2016,9:7331-7335
juvant chemotherapy after radical hysterectomy for FIGO
[13] GRIEMEL E R,WINTER R,KAPP K S,et al. Quality of
stage ⅠB⁃ⅡA cervical cancer:comparison with adjuvant
life and sexual functioning after cervical cancer treat⁃
RT/CCRT using inverse⁃probability⁃of⁃treatment weight⁃
ment:a long ⁃ term follow ⁃ up study[J]. Psycho Oncol,
ing[J]. PLoS One,2015,10(7):e0132298
2009,18(5):476-482
[6] MATSUO K,SHIMADA M,YOKOTA H,et al. Effective⁃
[14] LI S,HU T,CHEN Y,et al. Adjuvant chemotherapy,a valu⁃
ness of adjuvant systemic chemotherapy for intermediate⁃
able alternative option in selected patients with cervical
risk stage Ⅰ B cervical cancer[J]. Oncotarget,2017,8
cancer[J]. PLoS One,2013,8(9):e73837
(63):106866-106875
[15] 陈钦清. 手术后不同辅助治疗方式对早期宫颈癌患者
[7] MATSUO K,SHIMADA M,AOKI Y,et al. Comparison of
性生活质量影响的研究[D]. 杭州:浙江大学,2016
adjuvant therapy for node⁃positive clinical stage ⅠB⁃ⅡB
[16] 张佳佳,季 诚. 宫颈癌术后下肢淋巴水肿功能锻炼的
cervical cancer:systemic chemotherapy versus pelvic irra⁃
研究进展[J]. 南京医科大学学报(自然科学版),2019,
diation[J]. Int J Cancer,2017,141(5):1042-1051
39(11):1692-1695
[8] SEKI T,TANABE H,NAGATA C,et al. Adjuvant thera⁃
[收稿日期] 2019-08-16
py after radical surgery for stage ⅠB⁃ⅡB cervical adeno⁃